Is the price fair?
What LNTH's price assumes
Lantheus Holdings, Inc. trades at 24.4× earnings against 24.4× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
24.4
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.4 · cheaper than the typical name in its group
- Price / sales
- 3.23
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.6%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +4.2%
Growth the price implies · The price pays for +4.2% free cash flow growth a year for a decade; the business has delivered +63% a year over the last three.
Details›
- Price / book2026-Q1
- 4.12
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.4
- Free cash flow, trailing twelve months
- $377M
- Market capitalisation
- $6.76B
- 3-year revenue growth
- +15%
- 3-year free cash flow growth
- +63%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $58.97 |
| Its own P/E history, median | $81.30 |
| Its own P/E history, upper quartile | $96.08 |
| 52-week range | $50.11 – $109.01 |
| Today | $100.82 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #25 of 28 by Smart Score